Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

LMTX

- PMLiVE

Novartis’ Cosentyx scores again in phase 3, strengthens approval claim

Scopes approval in non-radiographic axial spondyloarthritis

- PMLiVE

Avanir’s week goes from bad to worse with Alzheimer’s stumble

Suffers a blow as second phase 3 trial misses the mark

- PMLiVE

AbbVie/Allergan’s merger faces public opposition

Advocacy groups and unions in the US express concerns

- PMLiVE

Novo follows Sanofi, Lilly with insulin price cut in US

Price cut will be effective from January 2020

- PMLiVE

Strike three for Rova-T has AbbVie cutting its losses

Will funnel R&D money into more promising projects

- PMLiVE

FDA clears Lilly’s Taltz for ankylosing spondylitis

New indication boosts $1bn+ hopes for this year

- PMLiVE

AbbVie scores FDA approval for arthritis treatment upadacitinib

Could find it difficult to live up to Humira

- PMLiVE

Imbruvica gains expanded use in Europe

Rival Calquence receives accelerated review in US

- PMLiVE

Lilly psoriasis drug beats J&J’s Tremfya in head-to-head trial

Shifting expectations in psoriasis outcomes

- PMLiVE

Eli Lilly scores positive phase 3 results for Emgality in treatment resistant migraine

Hopes to catch up with rivals in the market

- PMLiVE

AbbVie files blockbuster hopeful elagolix for uterine fibroids

Will face competition from Myovant rival

- PMLiVE

Lilly boosted by survival data for key growth drug Verzenio

Chases Pfizer's Ibrance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links